Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Share-based Compensation (2019 - 2025)

Allogene Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $8.7 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 35.37% year-over-year to $8.7 million; the TTM value through Sep 2025 reached $42.4 million, down 21.66%, while the annual FY2024 figure was $51.7 million, 21.54% down from the prior year.
  • Share-based Compensation for Q3 2025 was $8.7 million at Allogene Therapeutics, roughly flat from $8.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $22.9 million in Q2 2022 and bottomed at $8.7 million in Q3 2025.
  • The 5-year median for Share-based Compensation is $16.6 million (2023), against an average of $16.4 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 33.93% in 2021 before it crashed 36.47% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $22.0 million in 2021, then decreased by 21.74% to $17.2 million in 2022, then decreased by 11.67% to $15.2 million in 2023, then fell by 15.49% to $12.9 million in 2024, then tumbled by 32.79% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Share-based Compensation are $8.7 million (Q3 2025), $8.7 million (Q2 2025), and $12.2 million (Q1 2025).